Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Lbp Am Sa

LBP AM SA decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 90.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,317 shares of the company's stock after selling 22,816 shares during the quarter. LBP AM SA's holdings in Neurocrine Biosciences were worth $256,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NBIX. Vanguard Group Inc. grew its stake in Neurocrine Biosciences by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company's stock valued at $1,381,331,000 after purchasing an additional 122,681 shares during the last quarter. Dodge & Cox grew its stake in Neurocrine Biosciences by 134.2% during the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock valued at $411,742,000 after purchasing an additional 1,728,605 shares during the last quarter. AQR Capital Management LLC grew its stake in Neurocrine Biosciences by 2.9% during the 4th quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company's stock valued at $258,926,000 after purchasing an additional 53,610 shares during the last quarter. Geode Capital Management LLC grew its stake in Neurocrine Biosciences by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company's stock valued at $255,523,000 after purchasing an additional 15,830 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Neurocrine Biosciences by 102.9% in the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock valued at $198,939,000 after buying an additional 739,199 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock traded down $1.46 during trading on Friday, reaching $133.46. 724,778 shares of the company were exchanged, compared to its average volume of 1,146,982. The stock's 50 day simple moving average is $124.19 and its two-hundred day simple moving average is $121.53. The company has a market capitalization of $13.21 billion, a P/E ratio of 45.24, a PEG ratio of 1.37 and a beta of 0.24. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The company had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. During the same period last year, the business earned $1.20 earnings per share. The firm's revenue was up 11.1% compared to the same quarter last year. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NBIX. Canaccord Genuity Group boosted their price objective on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Wall Street Zen cut Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Evercore ISI decreased their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. The Goldman Sachs Group began coverage on Neurocrine Biosciences in a report on Thursday. They issued a "buy" rating and a $182.00 price objective for the company. Finally, Piper Sandler reissued an "overweight" rating and issued a $154.00 price objective (down previously from $160.00) on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $163.91.

Insider Buying and Selling

In related news, Director Kevin Charles Gorman sold 9,613 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the completion of the sale, the director directly owned 514,596 shares of the company's stock, valued at approximately $61,947,066.48. This trade represents a 1.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ingrid Delaet sold 457 shares of the firm's stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the sale, the insider directly owned 4,730 shares of the company's stock, valued at $638,550. The trade was a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 120,251 shares of company stock valued at $14,978,602 over the last 90 days. Insiders own 4.80% of the company's stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.